Alan Cantillep, MD
Nephrology · Fountain Valley, CANPI 1639517808
Payments from drug & device makers
Across 195 payments — averaging $7688.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1.4M
- Astellas Pharma Inc$58K
- Merck$49K
- Novartis$19K
- Astellas Pharma Global Development$6K
- Vifor Pharma, Inc.$797
- plus $3K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 33 | $1,364,070 |
| Astellas Pharma Inc | 14 | $57,838 |
| Merck | 3 | $48,940 |
| Novartis | 5 | $18,513 |
| Astellas Pharma Global Development | 2 | $6,298 |
| Vifor Pharma, Inc. | 27 | $797 |
| Otsuka America Pharmaceutical, Inc. | 14 | $383 |
| Akebia Therapeutics Inc | 16 | $330 |
| Aurinia Pharma U.S., Inc. | 15 | $322 |
| Amgen(2 entities) | 12 | $260 |
| Fresenius USA Marketing, Inc. | 10 | $197 |
| Bayer | 7 | $155 |
| La Jolla Pharmaceutical Company | 3 | $151 |
| Veloxis Pharmaceuticals, Inc. | 2 | $146 |
| Mallinckrodt Hospital Products Inc. | 6 | $144 |
| OPKO Pharmaceuticals, LLC | 6 | $134 |
| Boston Scientific | 1 | $118 |
| AstraZeneca | 4 | $85 |
| Baxter Healthcare | 1 | $72 |
| Calliditas Therapeutics US Inc. | 3 | $66 |
| Mallinckrodt Enterprises LLC | 3 | $60 |
| Lilly USA, LLC | 1 | $34 |
| Nxstage Medical, Inc. | 1 | $33 |
| Sanofi | 1 | $25 |
| GSK | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
How this compares
$1,499,263 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fountain Valley
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.